Albert Seymour
Chief Executive Officer at Seamless Therapeutics
Net worth: 213 741 $ as of 31/05/2024
Profile
Albert Seymour is currently the President & Chief Executive Officer at Seamless Therapeutics and a Director at Ensoma, Inc. Previously, he served as the President, Chief Executive Officer & Director at Homology Medicines, Inc. from 2016 to 2023 and as the Senior VP, Head-Global Research & Nonclinical at Shire Pharmaceuticals, Inc. from 2011 to 2016.
Dr. Seymour holds a doctorate degree from the University of Pittsburgh, a graduate degree from The Johns Hopkins University, and an undergraduate degree from the University of Delaware.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
0.07% | 06/09/2023 | 8,382 ( 0.07% ) | 213 741 $ | 31/05/2024 |
Albert Seymour active positions
| Companies | Position | Start |
|---|---|---|
Ensoma, Inc.
 Ensoma, Inc. Miscellaneous Commercial ServicesCommercial Services Ensoma, Inc. believes in the future of medicine and is committed to creating a new therapeutic category to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions. Ensoma is based in Boston, MA and has subsidiaries in Denmark. The company's engenious™ platform combines innovative delivery technology with the full DNA editing toolkit to address these disorders. Ensoma is supported by top-tier investors, a strategic collaboration with Takeda, and a passionate team. The company was founded by André Lieber, Hans-Peter Kiem, Kush M. Parmar, and the CEO is Emile F. Nuwaysir. | Director/Board Member | - |
Seamless Therapeutics
 Seamless Therapeutics Packaged SoftwareTechnology Services Seamless Therapeutics is a German company that is changing the paradigm of gene editing by unlocking the full potential of recombinases. The company is based in Dresden, Germany. The company is developing a pipeline of disease-modifying product candidates across a broad spectrum of indications to expand the therapeutic potential of gene editing. | Chief Executive Officer | 23/04/2024 |
Former positions of Albert Seymour
| Companies | Position | End |
|---|---|---|
| Q32 BIO INC. | Chief Executive Officer | 17/11/2023 |
Shire Pharmaceuticals, Inc.
 Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Corporate Officer/Principal | 01/03/2016 |
Training of Albert Seymour
| University of Delaware | Undergraduate Degree |
| The Johns Hopkins University | Graduate Degree |
| University of Pittsburgh | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
Homology Medicines, Inc.
 Homology Medicines, Inc. Pharmaceuticals: MajorHealth Technology Homology Medicines, Inc. is a clinical-stage genetic medicines company, which engages in the translation of proprietary gene editing and gene therapy technology into novel treatments for patients with rare genetic diseases. The company was founded in March 2015 and is headquartered in Bedford, MA. | Health Technology |
Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Health Technology |
Ensoma, Inc.
Ensoma, Inc. Miscellaneous Commercial ServicesCommercial Services Ensoma, Inc. believes in the future of medicine and is committed to creating a new therapeutic category to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions. Ensoma is based in Boston, MA and has subsidiaries in Denmark. The company's engenious™ platform combines innovative delivery technology with the full DNA editing toolkit to address these disorders. Ensoma is supported by top-tier investors, a strategic collaboration with Takeda, and a passionate team. The company was founded by André Lieber, Hans-Peter Kiem, Kush M. Parmar, and the CEO is Emile F. Nuwaysir. | Commercial Services |
Seamless Therapeutics
Seamless Therapeutics Packaged SoftwareTechnology Services Seamless Therapeutics is a German company that is changing the paradigm of gene editing by unlocking the full potential of recombinases. The company is based in Dresden, Germany. The company is developing a pipeline of disease-modifying product candidates across a broad spectrum of indications to expand the therapeutic potential of gene editing. | Technology Services |
- Stock Market
- Insiders
- Albert Seymour
